Phase 3 Study of Adjuvant Endocrine Therapy vs. Imlunestrant

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

For More information:

https://clinicaltrials.gov/ct2/show/NCT05514054?term=Adjuvant+Imlunestrant+vs+Standard+Adjuvant+Endocrine+Therapy+in+breast+cancer&draw=2&rank=1